Standard Treatment Approaches
At a Glance
Treatment for familial thrombomodulin anomalies depends on whether a THBD mutation causes clotting-related aHUS or bleeding-related TM-AC. aHUS usually requires urgent C5 inhibitor therapy, while TM-AC needs individualized specialist planning for bleeding and surgery.
Because a THBD mutation can lead to either a clotting disorder (aHUS) or a bleeding disorder (TM-AC), the treatment strategies are radically different. For those with the clotting phenotype, treatment is standardized and urgent, while the bleeding phenotype requires highly specialized, case-by-case management [1][2].
Treating the Clotting Phenotype (aHUS)
If you are clinically suspected of or diagnosed with complement-mediated aHUS, the goal is to stop your immune system (the complement system) from attacking your blood vessels and organs. This is done using a class of medications called C5 inhibitors [3].
- Standard Medications: The two primary treatments are eculizumab and ravulizumab. Eculizumab is typically given as an intravenous (IV) infusion once a week for the first month, then every two weeks. Ravulizumab is a newer, longer-acting version given every 4 to 8 weeks [4][5].
- The 24-Hour Goal: In a crisis, starting these medications as soon as possible—ideally within 24 hours of a suspected diagnosis—is associated with significantly better kidney recovery [1].
- Critical Safety Requirement: C5 inhibitors make you much more vulnerable to a rare but life-threatening infection called meningococcal disease [6]. Vaccination is ideally completed at least two weeks before treatment when clinically feasible, but life-saving treatment should not be delayed when urgent therapy is indicated. Vaccines and preventative antibiotics do not eliminate meningococcal risk. If you develop an urgent symptom like fever, severe headache, neck stiffness, rash, or rapidly worsening illness, seek emergency care immediately [6][7].
Managing the Bleeding Phenotype (TM-AC)
Treating Thrombomodulin-Associated Coagulopathy (TM-AC) is more complex because “standard” treatments for bleeding often fail to fully correct the problem.
In laboratory models of this condition, common “bypassing agents” like recombinant factor VIIa (rFVIIa) or activated prothrombin complex concentrate (aPCC) were only able to partially fix the clotting defect in laboratory models [2]. More importantly, these drugs did not fix the delayed fibrinolysis—the problem where the body takes too long to break down old clots—which can cause its own set of complications [2][8].
However, clinical management relies on specialized selection of rFVIIa, aPCC, antifibrinolytics, or factor products [2][8]. Any major surgery must be managed by a specialized team using an individualized hemostasis emergency plan, and you should never self-start medications like tranexamic acid, NSAIDs, or aspirin [9].
Duration of Treatment and Stopping Therapy
A common question for those with aHUS is how long they must stay on medication. There is no single “rule” for everyone, but the following guidelines generally apply [10]:
- Initial Phase: There is no universal requirement that all patients receive at least 6 to 12 months; duration depends on genetic risk, prior relapses, and trigger. Some patients need prolonged or lifelong treatment [10].
- Deciding to Stop: If your kidney function has normalized and you have not had a relapse, you and your doctor may discuss stopping the medication. This decision depends on your specific genetic risk factors and whether your aHUS was triggered by a one-time event (like pregnancy) or an ongoing vulnerability [11][12].
- Monitoring After Stopping: If you stop treatment, you will need “high-intensity” monitoring. Relapse rates vary, and relapse can cause irreversible kidney injury. Patients must never stop treatment without their specialist’s plan. Home urine dipsticks cannot replace blood pressure, blood, kidney-function, and urine-protein monitoring [13][14][15].
Common questions in this guide
What is the usual treatment for THBD-related aHUS?
What infection precautions are needed with C5 inhibitors?
How is bleeding from TM-AC treated?
How long might I need a C5 inhibitor for aHUS?
What monitoring is needed if aHUS treatment is stopped?
What should I do before surgery if I have TM-AC?
Get notified when new evidence is published on Familial thrombomodulin anomalies.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study.
Brocklebank V, Walsh PR, Smith-Jackson K, et al.
Blood 2023; (142(16)):1371-1386 doi:10.1182/blood.2022018833.
PMID: 37369098 - 2
Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.
Burley K, Whyte CS, Westbury SK, et al.
Blood 2016; (128(14)):1879-1883 doi:10.1182/blood-2016-05-716092.
PMID: 27436851 - 3
Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies.
Song JY
Childhood kidney diseases 2025; (29(2)):52-59 doi:10.3339/ckd.25.017.
PMID: 42779682 - 4
Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.
García Monteavaro C, Peralta Roselló C, Quiroga B, et al.
Case reports in nephrology 2016; (2016()):7471082 doi:10.1155/2016/7471082.
PMID: 28025630 - 5
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Tanaka K, Adams B, Aris AM, et al.
Pediatric nephrology (Berlin, Germany) 2021; (36(4)):889-898 doi:10.1007/s00467-020-04774-2.
PMID: 33048203 - 6
Beyond Vaccination: Persistent Meningococcal Risk in Anti-C5-Treated aHUS-Case Report and Review of Literature.
Matarese S, Brisca G, Moscatelli A, et al.
Journal of clinical medicine 2026; (15(8)) doi:10.3390/jcm15083048.
PMID: 42074848 - 7
Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.
Cullinan N, Gorman KM, Riordan M, et al.
Pediatrics 2015; (135(6)):e1506-9 doi:10.1542/peds.2014-3503.
PMID: 25941307 - 8
A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
Westbury SK, Whyte CS, Stephens J, et al.
Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.
PMID: 32634856 - 9
A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.
Okada M, Tominaga N, Honda G, et al.
Blood advances 2020; (4(12)):2631-2639 doi:10.1182/bloodadvances.2019001155.
PMID: 32556284 - 10
Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults.
Ávila A, Cao M, Espinosa M, et al.
Frontiers in medicine 2023; (10()):1264310 doi:10.3389/fmed.2023.1264310.
PMID: 38105887 - 11
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.
Bryant A, Lecouturier J, Orozco-Leal G, et al.
The Lancet regional health. Europe 2025; (56()):101392 doi:10.1016/j.lanepe.2025.101392.
PMID: 41550273 - 12
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J, Delmas Y, Fakhouri F, et al.
BMC nephrology 2019; (20(1)):125 doi:10.1186/s12882-019-1314-1.
PMID: 30971227 - 13
Haemoglobinuria for the early identification of aHUS relapse: data from the ItalKId-HUS Network.
Brambilla M, Ardissino G, Paglialonga F, et al.
Journal of nephrology 2022; (35(1)):279-284 doi:10.1007/s40620-021-00965-8.
PMID: 33459950 - 14
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F, Fila M, Hummel A, et al.
Blood 2021; (137(18)):2438-2449 doi:10.1182/blood.2020009280.
PMID: 33270832 - 15
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F, Fila M, Provôt F, et al.
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.
PMID: 27799617
This page is for informational purposes only and does not constitute medical advice about familial thrombomodulin anomalies. Decisions about C5 inhibitors, bleeding treatment, surgery, or stopping therapy should be made with your specialist team.